Pfizer Lyme Vaccine Shows 70% Efficacy But Misses Statistical Goal
Pfizer and Valneva's Lyme disease vaccine reduced infection risk by over 70%, but failed to meet its prespecified statistical threshold in clinical trials.
The latest infectious disease coverage from Hawaii Medical Journal.
Pfizer and Valneva's Lyme disease vaccine reduced infection risk by over 70%, but failed to meet its prespecified statistical threshold in clinical trials.
Insmed's Arikayce met primary endpoints in a phase 3 trial for treatment-naive MAC lung infection patients, improving symptoms and culture conversion rates.